Long-term Safety of Subjects Continuing Dolutegravir After Participation in Clinical Studies of Dolutegravir in Russian Federation
Phase of Trial: Phase IV
Latest Information Update: 12 Feb 2019
Price : $35 *
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors ViiV Healthcare
- 31 Jan 2019 Status changed from active, no longer recruiting to completed.
- 27 Aug 2018 Planned End Date changed from 14 Sep 2018 to 31 Oct 2018.
- 27 Aug 2018 Planned primary completion date changed from 14 Sep 2018 to 31 Oct 2018.